Chemotherapy Boosts Survival for Older Patients With TNBC

Published Date: 08 Apr 2026

Patients aged 70 years or older stand to benefit from adjuvant chemotherapy for triple-negative breast cancer, but the majority do not receive it.

Read Full News

Latest News

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

When Healthcare Chatbots Fall Short of Human Connection

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

FDA Advisors Split on Regimens for Breast, Prostate Cancers

The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Combo Therapy Boosts Early CML Response but Not Long Term

A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

Todays Updates

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Todays Updates

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Latest News

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

News All Time

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

Photopenia in high CT density renal lesions on [18F]FDG PET/CT scans shows a high negative predictive value for excluding malignancy.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Can Oncotype Predict Recurrence Risk in Older BC Patients?

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Is Vitamin D a Key to Better Breast Cancer Survival?

A prospective study links sufficient vitamin D levels at the time of breast cancer diagnosis to improved overall survival.

Where Does Mistletoe Extract Fit in Supportive Cancer Care?

Mistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, limiting its role in routine oncology care.

A Chemo-Free Option for Some Advanced Endometrial Cancers?

A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.

Early Tislelizumab May Boost PFS in Esophageal Cancer

For patients with locally advanced esophageal cancer, front-loading immunotherapy with induction chemo and chemoradiotherapy, without maintenance immunotherapy, may improve outcomes.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

Recommended News For You

Durvalumab Wins FDA Approval in Limited-Stage SCLC

Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer

SCOTUS Grapples With Multibillion-Dollar Lawsuits Over Roundup Cancer Claims

Clinical trial could lead to new 'gold standard' test for prostate cancer detection

The Risk of Major Mortality is Associated with the Start of Opioids in Dementia.

Why breast cancer survivors don't take their medicine, and what can be done about it.

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

Recommended Articles For You

The Statistical Paradigm of Leukemia: From Evolving Epidemiology and Molecular Stratification to Precision Therapies and Future Horizons in Leukemia 

Cancer Diagnosis in 2025: Innovations, Education, and Evolving Clinical Strategies 

IGSF8: A Rising Star in Cancer Immunotherapy - Harnessing the Innate Immune System 

Understanding the Rare Disease: Werner Syndrome Explained  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Radiation therapy can promote amphiregulin, which increases growth of metastases

3.

For cancer patients who are not responding to chemotherapy, new genes and natural toxins offer hope.

4.

DNA origami offers more accurate imaging in the fight against pancreatic cancer

5.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

1.

Colon Cancer Staging: What You Need to Know

2.

Exploring the Potential of Xospata: A New Frontier in Cancer Treatment

3.

Understanding QSOFA: A Vital Tool for Recognizing Sepsis 

4.

Everything You Need to Know About HTLV: A Comprehensive Guide 

5.

Uncovering the Mysteries of the RDW Blood Test

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part III

2.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I

4.

Understanding the causes of anemia in adults beyond nutritional deficiencies

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot